

## New therapeutic approaches in targeted therapy for renal cell carcinoma

Poster Session 64

Monday, 27 March  
12:15 - 13:45

**Location:** Room Berlin, North Hall (Level 1)

**Chairs:** N. Kröger, Greifswald (DE)  
A. Necchi, Milan (IT)  
G. Stewart, Cambridge (GB)

**Aims and objectives of this session**

To discuss new therapeutic approaches based on basic research results.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 842 **Impact of intratumoral heterogeneity of renal cancer on drug response and development of resistance in patient derived xenografts**  
By: Bedke J.<sup>1</sup>, Flechsig S.<sup>2</sup>, Hennenlotter J.<sup>1</sup>, Wulf-Goldenberg A.<sup>2</sup>, Jandrig A.<sup>3</sup>, Schostak M.<sup>3</sup>, Becker M.<sup>2</sup>, Fichtner I.<sup>2</sup>, Zeisig R.<sup>2</sup>, Hoffmann J.<sup>2</sup>, Schmees C.<sup>4</sup>, Stenzl A.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Tübingen, Dept. of Urology, Tübingen, Germany, <sup>2</sup>EPO GmbH, Berlin-Buch, Berlin, Germany, <sup>3</sup>University of Magdeburg, Dept. of Urology, Magdeburg, Germany, <sup>4</sup>Natural and Medical Sciences Institute, Dept. of Molecular Biology, Reutlingen, Germany
- 843 **Pathological and prognostic significance of densities of CD57+ (natural killer cells), CD68+ (macrophage), and mast cells in renal cell carcinoma tissues**  
By: Mochizuki Y., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Oba K., Sakai H.  
**Institutes:**Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan
- 844 **A microplate co-culture assay allows individualised compound efficacy testing in patients derived 3D tumour spheroids and autologous immune cells**  
By: Bedke J.<sup>1</sup>, Bodenhöfer M.<sup>2</sup>, Harland N.<sup>1</sup>, Hennenlotter J.<sup>1</sup>, Anderle N.<sup>2</sup>, Schmees C.<sup>2</sup>, Stenzl A.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Tübingen, Dept. of Urology, Tübingen, Germany, <sup>2</sup>Natural and Medical Sciences Institute At The University of Tübingen, Dept. of Molecular Biology, Reutlingen, Germany
- 845 **Enhanced RCC cell killing with natural killer cells generated from CD34+ hematopoietic progenitor cells combined with mAb cG250**  
By: Oosterwijk-Wakka J.<sup>1</sup>, Cany J.<sup>2</sup>, Sabata Pérez H.<sup>1</sup>, Dolstra H.<sup>2</sup>, Mulders P.<sup>1</sup>, Oosterwijk E.<sup>1</sup>  
**Institutes:**<sup>1</sup>Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, <sup>2</sup>Radboudumc, Dept. of Hematology, Nijmegen, The Netherlands
- 846 **Orthotopic sunitinib resistant renal cell carcinoma xenograft mouse model**  
By: Frees S., Moskalev I., Raven P., D'Costa N., Tan Z., Struss W., Chavez-Munoz C., So A.  
**Institutes:**The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- 847 **Inhibition of semaphorin 3C augments the anti-cancer effect of sunitinib in renal cancer**  
By: Dejima T.<sup>1</sup>, Takeuchi A.<sup>1</sup>, Eto M.<sup>1</sup>, Naito S.<sup>1</sup>, Gleave M.<sup>2</sup>, Ong C.<sup>2</sup>  
**Institutes:**<sup>1</sup>Kyushu University, Dept. of Urology, Fukuoka, Japan, <sup>2</sup>The Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada
- 848 **Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors**  
By:

Takuto H., Miyake H., Nakano Y., Fujisawa M.

**Institutes:**Kobe University Graduate School of Medicine, Division of Urology, Dept. of Surgery Related, Kobe, Japan

- 849 **Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo**  
**By:** Frees S.<sup>1</sup>, Chavez-Munoz C.<sup>1</sup>, Zhou B.<sup>1</sup>, Raven P.<sup>1</sup>, Fazli L.<sup>1</sup>, Chi K.<sup>1</sup>, Lawson K.<sup>2</sup>, Finelli A.<sup>2</sup>, Gleave M.<sup>1</sup>, So A.<sup>1</sup>  
**Institutes:**<sup>1</sup>The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, <sup>2</sup>University of Toronto, Dept. of Surgical Oncology,, Toronto, Canada
- 850 **Metformin drives synergistic effect and overcomes the treatment resistance of molecular targeted drugs for renal cell carcinoma**  
**By:** Matsumoto H., Mori J., Shimizu K., Fujii N., Kawai Y., Inoue R., Yamamoto Y., Hirata H., Shimabukuro T., Matsuyama H.  
**Institutes:**Yamaguchi University, Graduate School of Medicine, Dept. of Urology, Ube, Japan
- 851 **Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress**  
**By:** Okubo K., Sato A., Asano T., Isono M., Asano T.  
**Institutes:**National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
- 852 **Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma**  
**By:** Abt D.<sup>1</sup>, Kraus M.<sup>2</sup>, Bader J.<sup>2</sup>, Besse A.<sup>2</sup>, Schmid H.-P.<sup>1</sup>, Engeler D.S.<sup>1</sup>, Driessen C.<sup>2</sup>, Besse L.<sup>2</sup>  
**Institutes:**<sup>1</sup>Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, <sup>2</sup>Kantonsspital St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland
- 853 **Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells**  
**By:** Sato A., Asano T., Okubo K., Isono M., Asano T.  
**Institutes:**National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
- 854 **Transcriptomic-metabolomic profiling revealed that fatty acid oxidation-induced stress causes cancer Cachexia**  
**By:** Fukawa T.<sup>1</sup>, Yan-Jiang B.C.<sup>4</sup>, Kanayama H.-O.<sup>2</sup>, Teh B.T.<sup>3</sup>, Shyh-Chang N.<sup>4</sup>  
**Institutes:**<sup>1</sup>Tokushima University Graduated School, Dept. of Urology, Tokushima, Japan, <sup>2</sup>Tokushima University Graduated School, Dept. Of Urology, Tokushima, Japan, <sup>3</sup>National Cancer Centre Singapore, Laboratory of Cancer Epigenome, Singapore, Singapore, <sup>4</sup>Genome Institute of Singapore, Agency For Science Technology and Research, Singapore, Singapore
- 13:30 - 13:37 **Summary**  
G. Stewart, Cambridge (GB)